These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 8623216)
21. Evolution of the therapeutic drug monitoring of cyclosporine. Citterio F Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378 [TBL] [Abstract][Full Text] [Related]
22. Suitable whole blood levels 2 hours after neoral in liver transplant patients: experiences at a single center. Kim KH; Lee SG; Lee YJ; Park KM; Hwang S; Ahn CS; Moon DB; Ha TY; Song KW; Kim DS; Jung DH; Kim BS; Moon KM; Lee HJ; Park JI; Ryu JH Transplant Proc; 2006 Nov; 38(9):2971-3. PubMed ID: 17112877 [TBL] [Abstract][Full Text] [Related]
23. Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral. Mendez R; Abboud H; Burdick J; Copley B; Freeman R; Batiuk TD; Cooney GF; Barbeito R Clin Ther; 1999 Jan; 21(1):160-71. PubMed ID: 10090433 [TBL] [Abstract][Full Text] [Related]
24. Therapeutic drug monitoring of cyclosporine. Jorga A; Holt DW; Johnston A Transplant Proc; 2004 Mar; 36(2 Suppl):396S-403S. PubMed ID: 15041374 [TBL] [Abstract][Full Text] [Related]
25. Cyclosporine peak levels provide a better correlation with the area-under-the-curve than trough levels in liver transplant patients treated with neoral. Cantarovich M; Barkun J; Besner JG; Metrakos P; Alpert E; Deschénes M; Aalamian Z; Tchervenkov JI Transplant Proc; 1998 Jun; 30(4):1462-3. PubMed ID: 9636593 [No Abstract] [Full Text] [Related]
26. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation. Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594 [TBL] [Abstract][Full Text] [Related]
27. The pharmacokinetics of equoral versus neoral in stable renal transplant patients: a multinational multicenter study. Masri MA; Haberal M; Rizvi A; Stephan A; Bilgin N; Naqvi A; Barbari A; Kamel G; Zafar N; Emiroğlu R; Colak T; Manzoor K; Matha V; Kamarad V; Rizk S; Itany AR; Shehedeh I Transplant Proc; 2004; 36(1):80-3. PubMed ID: 15013306 [TBL] [Abstract][Full Text] [Related]
28. Comparison of the long-term tolerability, pharmacodynamics, and safety of Sandimmune and Neoral in liver transplant recipients. Ontario Liver Transplant Study Group. Grant D; Rochon J; Levy G Transplant Proc; 1996 Aug; 28(4):2232-3. PubMed ID: 8769208 [No Abstract] [Full Text] [Related]
29. Conversion from Sandimmune to Neoral in stable renal and pancreas transplant recipients enhances cyclosporine absorption. Chapman JR; O'Connell PJ; Bovington KJ; Allen RD Transplant Proc; 1996 Aug; 28(4):2293-5. PubMed ID: 8769229 [No Abstract] [Full Text] [Related]
30. Conversion from cyclosporine to Neoral in pediatric recipients for kidney, liver, and heart transplantation. Holmberg C; Laine J; Jalanko H; Leijala M; Hoppu K Transplant Proc; 1996 Aug; 28(4):2262-3. PubMed ID: 8769219 [No Abstract] [Full Text] [Related]
31. Conversion from Sandimmune to Neoral in stable liver graft recipients. Pollard SG; Lodge JP Transplant Proc; 1996 Aug; 28(4):2244-6. PubMed ID: 8769213 [No Abstract] [Full Text] [Related]
32. Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. Dotti G; Gaspari F; Caruso R; Perico N; Remuzzi G; Barbui T; Rambaldi A Haematologica; 2001 Mar; 86(3):311-5. PubMed ID: 11255279 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of Neoral in the immediate postoperative period in children post-liver transplantation. van Mourik ID; Melendez HV; Thomson M; Mieli-Vergani G; Heaton N; Kelly DA Liver Transpl Surg; 1998 Nov; 4(6):491-8. PubMed ID: 9791160 [TBL] [Abstract][Full Text] [Related]
34. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289 [TBL] [Abstract][Full Text] [Related]
35. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients. Diciolla F; Scolletta S; Berti L; Maccherini M; Federici D; Bernazzali S; Lisi G; Chiavarelli M Transplant Proc; 2005 Mar; 37(2):1355-9. PubMed ID: 15848719 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy. Nakamura Y; Takeuchi H; Okuyama K; Akashi T; Jojima Y; Konno O; Akashi I; Hama K; Iwahori T; Ashizawa T; Hirano T; Oka K; Matsuno N; Nagao T Transplant Proc; 2005 May; 37(4):1725-7. PubMed ID: 15919445 [TBL] [Abstract][Full Text] [Related]
37. Neoral use in the cardiac transplant recipient. Valantine H Transplant Proc; 2000 May; 32(3A Suppl):27S-44S. PubMed ID: 10814748 [TBL] [Abstract][Full Text] [Related]
38. Investigation of the pharmacokinetics of cyclosporine in patients following long-term administration after a kidney transplant: comparison of Neoral and Sandimmune. Takahara S; Ichimaru N; Kojima Y; Namba Y; Toki K; Shi Y; Yoshimura K; Matsumiya K; Nonomura N; Okuyama A Transplant Proc; 2004 Mar; 36(2 Suppl):456S-460S. PubMed ID: 15041387 [TBL] [Abstract][Full Text] [Related]
39. Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with Sandimmune-Neoral. Serafinowicz A; Gaciong Z; Baçzkowska T; Rell K; Lao M; Wałaszewski J Transplant Proc; 1996 Dec; 28(6):3138-9. PubMed ID: 8962216 [No Abstract] [Full Text] [Related]
40. Use of cyclosporine microemulsion (Neoral) in de novo and stable renal transplantation: clinical impact, pharmacokinetic consequences and economic benefits. Canadian and International Neoral Study Groups. Keown PA Transplant Proc; 1996 Aug; 28(4):2147-50. PubMed ID: 8769183 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]